Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Journal of Diabetes & Metabolic Disorders
Published in: Journal of Diabetes & Metabolic Disorders 2/2019

01-12-2019 | Obesity | Review article

Inflammation related miRNAs as an important player between obesity and cancers

Authors: Morteza Gholami, Bagher Larijani, Zhila Zahedi, Fatemeh Mahmoudian, Samira Bahrami, Sima Parvizi Omran, Zahra Saadatian, Shirin Hasani-Ranjbar, Reza Taslimi, Milad Bastami, Mahsa M. Amoli

Published in: Journal of Diabetes & Metabolic Disorders | Issue 2/2019

Login to get access

Abstract

The growing trend in addition to their burden, prevalence, and death has made obesity and cancer two of the most concerning diseases worldwide. Obesity is an important risk factor for common types of cancers where the risk of some cancers is directly related to the obesity. Various inflammatory mechanisms and increased level of pro-inflammatory cytokines have been investigated in many previous studies, which play key roles in the pathophysiology and development of both of these conditions. On the other hand, in the recent years, many studies have individually focused on the biomarker’s role and therapeutic targeting of microRNAs (miRNAs) in different types of cancers and obesity including newly discovered small noncoding RNAs (sncRNAs) which regulate gene expression and RNA silencing. This study is a comprehensive review of the main inflammation related miRNAs in obesity/obesity related traits. For the first time, the main roles of miRNAs in obesity related cancers have been discussed in response to the question raised in the following hypothesis; do the main inflammatory miRNAs link obesity with obesity-related cancers regarding their role as biomarkers?
Footnotes
1
Circulating micro RNA
 
Literature
1.
Weir HK, Anderson RN, King SMC, Soman A, Thompson TD, Hong Y et al. Peer Reviewed: Heart Disease and Cancer Deaths—Trends and Projections in the United States, 1969–2020. Preventing chronic disease. 2016;13.
2.
3.
Hansson GK, Hermansson A. The immune system in atherosclerosis. Nat Immunol. 2011;12(3):204.PubMed
4.
Dean E, Gormsen Hansen R. Prescribing optimal nutrition and physical activity as “first-line” interventions for best practice management of chronic low-grade inflammation associated with osteoarthritis: evidence synthesis. Arthritis. 2012;2012.
5.
Lee Y-H, Pratley RE. The evolving role of inflammation in obesity and the metabolic syndrome. Current diabetes reports. 2005;5(1):70–5.PubMed
6.
Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342(12):836–43.PubMed
7.
8.
Asterholm IW, Tao C, Morley TS, Wang QA, Delgado-Lopez F, Wang ZV, et al. Adipocyte inflammation is essential for healthy adipose tissue expansion and remodeling. Cell Metab. 2014;20(1):103–18.PubMedCentral
9.
Korniluk A, Koper O, Kemona H, Dymicka-Piekarska V. From inflammation to cancer. Irish Journal of Medical Science (1971-). 2017;186(1):57–62.
10.
Vendramini-Costa BD, Carvalho EJ. Molecular link mechanisms between inflammation and cancer. Curr Pharm Des. 2012;18(26):3831–52.PubMed
11.
12.
Iyengar NM, Gucalp A, Dannenberg AJ, Hudis CA. Obesity and cancer mechanisms: tumor microenvironment and inflammation. J Clin Oncol. 2016;34(35):4270.PubMedPubMedCentral
13.
Bertoli G, Cava C, Castiglioni I. MicroRNAs: new biomarkers for diagnosis, prognosis, therapy prediction and therapeutic tools for breast cancer. Theranostics. 2015;5(10):1122.PubMedPubMedCentral
14.
Cheng G. Circulating miRNAs: roles in cancer diagnosis, prognosis and therapy. Adv Drug Deliv Rev. 2015;81:75–93.PubMed
15.
Amin MN, Hussain MS, Sarwar MS, Moghal MMR, Das A, Hossain MZ et al. How the association between obesity and inflammation may lead to insulin resistance and cancer. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2019.
16.
Deng T, Lyon CJ, Bergin S, Caligiuri MA, Hsueh WA. Obesity, inflammation, and cancer. Annual Review of Pathology: Mechanisms of Disease. 2016;11:421–49.
17.
Zhong H, Ma M, Liang T, Guo L. Role of microRNAs in obesity-induced metabolic disorder and immune response. Journal of immunology research. 2018;2018.
18.
19.
Cirillo F, Catellani C, Sartori C, Lazzeroni P, Amarri S, Street ME. Obesity, insulin resistance, and colorectal Cancer: could miRNA dysregulation play a role? Int J Mol Sci. 2019;20(12):2922.PubMedCentral
20.
Sargent J. Rethinking inflammation and adipocyte homeostasis. Nat Rev Endocrinol. 2014;10(8):446–7.PubMed
21.
Wagner M, Bjerkvig R, Wiig H, Melero-Martin JM, Lin R-Z, Klagsbrun M, et al. Inflamed tumor-associated adipose tissue is a depot for macrophages that stimulate tumor growth and angiogenesis. Angiogenesis. 2012;15(3):481–95.PubMedPubMedCentral
22.
Divella R, De Luca R, Abbate I, Naglieri E, Daniele A. Obesity and cancer: the role of adipose tissue and adipo-cytokines-induced chronic inflammation. J Cancer. 2016;7(15):2346.PubMedPubMedCentral
23.
Okada F. Inflammation-related carcinogenesis: current findings in epidemiological trends, causes and mechanisms. Yonago Acta Medica. 2014;57(2):65.PubMedPubMedCentral
24.
Picon-Ruiz M, Morata-Tarifa C, Valle-Goffin JJ, Friedman ER, Slingerland JM. Obesity and adverse breast cancer risk and outcome: mechanistic insights and strategies for intervention. CA Cancer J Clin. 2017;67(5):378–97.PubMedPubMedCentral
25.
26.
Fischer-Posovszky P, Wabitsch M, Hochberg Z. Endocrinology of adipose tissue-an update. Horm Metab Res. 2007;39(05):314–21.PubMed
27.
28.
Reynisdottir S, Langin D, Carlström K, Holm C, Rössner S, Arner P. Effects of weight reduction on the regulation of lipolysis in adipocytes of women with upper-body obesity. Clin Sci. 1995;89(4):421–9.PubMed
29.
Howe LR, Subbaramaiah K, Hudis CA, Dannenberg AJ. Molecular pathways: adipose inflammation as a mediator of obesity-associated cancer. Clinical cancer research. 2013:clincanres. 2603.013.
30.
Aggarwal BB, Shishodia S, Sandur SK, Pandey MK, Sethi G. Inflammation and cancer: how hot is the link? Biochem Pharmacol. 2006;72(11):1605–21.PubMed
31.
Thun MJ, Henley SJ, Gansler T, editors. Inflammation and cancer: an epidemiological perspective. Novartis Foundation symposium; 2004: Chichester; New York; John Wiley; 1999.
32.
Zhang Q, Xie W, Wang F, Li RH, Cui L, Wang H, et al. Epidemiological investigation and risk factors for cervical lesions: cervical Cancer screening among women in rural areas of Henan Province China. Medical Science Monitor : International Medical Journal of Experimental and Clinical Research. 2016;22:1858–65. https://​doi.​org/​10.​12659/​MSM.​894663.CrossRef
33.
34.
35.
Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454(7203):436.PubMed
36.
Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest. 2003;112(12):1821–30.PubMedPubMedCentral
37.
Trayhurn P, Wood IS. Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr. 2004;92(3):347–55.PubMed
38.
Jung U, Choi M-S. Obesity and its metabolic complications: the role of adipokines and the relationship between obesity, inflammation, insulin resistance, dyslipidemia and nonalcoholic fatty liver disease. Int J Mol Sci. 2014;15(4):6184–223.PubMedPubMedCentral
39.
Schäffler A, Schölmerich J, Buechler C. Mechanisms of disease: adipokines and breast cancer—endocrine and paracrine mechanisms that connect adiposity and breast cancer. Nat Rev Endocrinol. 2007;3(4):345.
40.
Harvie M, Howell A. Energy balance adiposity and breast cancer–energy restriction strategies for breast cancer prevention. Obes Rev. 2006;7(1):33–47.PubMed
41.
Deng T, Lyon CJ, Minze LJ, Lin J, Zou J, Liu JZ, et al. Class II major histocompatibility complex plays an essential role in obesity-induced adipose inflammation. Cell Metab. 2013;17(3):411–22.PubMedPubMedCentral
42.
Carbone F, La Rocca C, Matarese G. Immunological functions of leptin and adiponectin. Biochimie. 2012;94(10):2082–8.PubMed
43.
Ekström M, Söderberg S, Tornvall P. Acute systemic inflammation is unlikely to affect adiponectin and leptin synthesis in humans. Frontiers in Cardiovascular Medicine. 2015;2:7.PubMedCentral
44.
Snoussi K, Strosberg AD, Bouaouina N, Ahmed SB, Helal AN, Chouchane L. Leptin and leptin receptor polymorphisms are associated with increased risk and poor prognosis of breast carcinoma. BMC Cancer. 2006;6(1):38.PubMedPubMedCentral
45.
Uddin S, P. P Bavi, Hussain AR, Alsbeih G, Al-Sanea N, Abdul Jabbar A et al. Leptin receptor expression in Middle Eastern colorectal cancer and its potential clinical implication. Carcinogenesis. 2009;30(11):1832–1840.PubMed
46.
Dieudonne M-N, Machinal-Quelin F, Serazin-Leroy V, Leneveu M-C, Pecquery R, Giudicelli Y. Leptin mediates a proliferative response in human MCF7 breast cancer cells. Biochem Biophys Res Commun. 2002;293(1):622–8.PubMed
47.
Mantovani G, Macciò A, Madeddu C, Mura L, Gramignano G, Lusso MR, et al. Quantitative evaluation of oxidative stress, chronic inflammatory indices and leptin in cancer patients: correlation with stage and performance status. Int J Cancer. 2002;98(1):84–91.PubMed
48.
Sánchez-Jiménez F, Pérez-Pérez A, de la Cruz-Merino L, Sánchez-Margalet V. Obesity and breast cancer: role of leptin. Frontiers in oncology. 2019;9.
49.
Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 1993;75(5):843–54.PubMed
50.
Reinhart BJ, Slack FJ, Basson M, Pasquinelli AE, Bettinger JC, Rougvie AE, et al. The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature. 2000;403(6772):901.PubMed
51.
Pasquinelli AE, Reinhart BJ, Slack F, Martindale MQ, Kuroda MI, Maller B, et al. Conservation of the sequence and temporal expression of let-7 heterochronic regulatory RNA. Nature. 2000;408(6808):86.PubMed
52.
Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci. 2002;99(24):15524–9.PubMed
53.
Xu P, Vernooy SY, Guo M, Hay BA. The Drosophila microRNA Mir-14 suppresses cell death and is required for normal fat metabolism. Curr Biol. 2003;13(9):790–5.PubMed
54.
Esau C, Kang X, Peralta E, Hanson E, Marcusson EG, Ravichandran LV, et al. MicroRNA-143 regulates adipocyte differentiation. J Biol Chem. 2004;279(50):52361–5.PubMed
55.
Kasiappan R, Rajarajan D. Role of microRNA regulation in obesity-associated breast cancer: nutritional perspectives. Adv Nutr. 2017;8(6):868–88.PubMedPubMedCentral
56.
Lawrie CH, Soneji S, Marafioti T, Cooper CD, Palazzo S, Paterson JC, et al. MicroRNA expression distinguishes between germinal center B cell-like and activated B cell-like subtypes of diffuse large B cell lymphoma. Int J Cancer. 2007;121(5):1156–61.PubMed
57.
Cirillo F, Lazzeroni P, Catellani C, Sartori C, Amarri S, Street ME. MicroRNAs link chronic inflammation in childhood to growth impairment and insulin-resistance. Cytokine Growth Factor Rev. 2018;39:1–18.PubMed
58.
Huang Y, Yan Y, Xv W, Qian G, Li C, Zou H et al. A New Insight into the Roles of MiRNAs in Metabolic Syndrome. BioMed Research International. 2018;2018.
59.
Heneghan H, Miller N, McAnena O, O'brien T, Kerin M. Differential miRNA expression in omental adipose tissue and in the circulation of obese patients identifies novel metabolic biomarkers. The Journal of Clinical Endocrinology & Metabolism. 2011;96(5):E846–E50.
60.
Klöting N, Berthold S, Kovacs P, Schön MR, Fasshauer M, Ruschke K, et al. MicroRNA expression in human omental and subcutaneous adipose tissue. PLoS One. 2009;4(3):e4699.PubMedPubMedCentral
61.
Strum JC, Johnson JH, Ward J, Xie H, Feild J, Hester A, et al. MicroRNA 132 regulates nutritional stress-induced chemokine production through repression of SirT1. Mol Endocrinol. 2009;23(11):1876–84.PubMedPubMedCentral
62.
Liu F, Li Y, Jiang R, Nie C, Zeng Z, Zhao N, et al. miR-132 inhibits lipopolysaccharide-induced inflammation in alveolar macrophages by the cholinergic anti-inflammatory pathway. Exp Lung Res. 2015;41(5):261–9.PubMed
63.
Ortega FJ, Mercader JM, Catalán V, Moreno-Navarrete JM, Pueyo N, Sabater M et al. Targeting the circulating microRNA signature of obesity. Clinical chemistry. 2013:clinchem. 2012.195776.
64.
Wang Y, Liang J, Qin H, Ge Y, Du J, Lin J, et al. Elevated expression of miR-142-3p is related to the pro-inflammatory function of monocyte-derived dendritic cells in SLE. Arthritis Research & Therapy. 2016;18(1):263.
65.
Li H, Guan S-B, Lu Y, Wang F. MiR-140-5p inhibits synovial fibroblasts proliferation and inflammatory cytokines secretion through targeting TLR4. Biomed Pharmacother. 2017;96:208–14.PubMed
66.
Villeneuve LM, Kato M, Reddy MA, Wang M, Lanting L, Natarajan R. Enhanced levels of microRNA-125b in vascular smooth muscle cells of diabetic db/db mice lead to increased inflammatory gene expression by targeting the histone methyltransferase Suv39h1. Diabetes. 2010;59(11):2904–15.PubMedPubMedCentral
67.
Duroux-Richard I, Roubert C, Ammari M, Présumey J, Grün JR, Häupl T et al. miR-125b controls monocyte adaptation to inflammation through mitochondrial metabolism and dynamics. Blood. 2016:blood-2016-02-697003.
68.
Wang Q, Navitskaya S, Chakravarthy H, Huang C, Kady N, Lydic TA, et al. Dual anti-inflammatory and anti-angiogenic action of miR-15a in diabetic retinopathy. EBioMedicine. 2016;11:138–50.PubMedPubMedCentral
69.
Wang X, Wang X, Liu X, Wang X, Xu J, Hou S, et al. miR-15a/16 are upreuglated in the serum of neonatal sepsis patients and inhibit the LPS-induced inflammatory pathway. Int J Clin Exp Med. 2015;8(4):5683.PubMedPubMedCentral
70.
Peng J, Zhou Y, Deng Z, Zhang H, Wu Y, Song T, et al. miR-221 negatively regulates inflammation and insulin sensitivity in white adipose tissue by repression of sirtuin-1 (SIRT1). J Cell Biochem. 2018;119(8):6418–28.PubMed
71.
Chou W-W, Wang Y-T, Liao Y-C, Chuang S-C, Wang S-N, Juo S-HH. Decreased microRNA-221 is associated with high levels of TNF-α in human adipose tissue-derived mesenchymal stem cells from obese woman. Cell Physiol Biochem. 2013;32(1):127–37.PubMed
72.
Hulsmans M, De Keyzer D, Holvoet P. MicroRNAs regulating oxidative stress and inflammation in relation to obesity and atherosclerosis. FASEB J. 2011;25(8):2515–27.PubMed
73.
Teng G-g, Wang W-h, Dai Y, Wang S-j, Chu Y-x, Li J. Let-7b is involved in the inflammation and immune responses associated with helicobacter pylori infection by targeting toll-like receptor 4. PLoS One. 2013;8(2):e56709.PubMedPubMedCentral
74.
Ti D, Hao H, Tong C, Liu J, Dong L, Zheng J, et al. LPS-preconditioned mesenchymal stromal cells modify macrophage polarization for resolution of chronic inflammation via exosome-shuttled let-7b. J Transl Med. 2015;13(1):308.PubMedPubMedCentral
75.
Brennan E, Wang B, McClelland A, Mohan M, Marai M, Beuscart O et al. Protective effect of Let-7 miRNA family in regulating inflammation in diabetes-associated atherosclerosis. Diabetes. 2017:db161405.
76.
77.
78.
79.
80.
Brettfeld C, Maver A, Aumuller E, Peterlin B, Haslberger AG. MicroRNAs Responsible for Inflammation in Obesity. 2017. 2017.
81.
Brettfeld C, Maver A, Aumuller E, Peterlin B, Haslberger AG. MicroRNAs responsible for inflammation in obesity. Journal of Endocrinology and Metabolism. 2017;7(3):77–85.
82.
Park H, Huang X, Lu C, Cairo MS, Zhou X. MicroRNA-146a and microRNA-146b regulate human dendritic cell apoptosis and cytokine production by targeting TRAF6 and IRAK1 proteins. J Biol Chem. 2015;290(5):2831–41.PubMed
83.
Shi C, Zhu L, Chen X, Gu N, Chen L, Zhu L, et al. IL-6 and TNF-α induced obesity-related inflammatory response through transcriptional regulation of miR-146b. J Interf Cytokine Res. 2014;34(5):342–8.
84.
Chartoumpekis DV, Zaravinos A, Ziros PG, Iskrenova RP, Psyrogiannis AI, Kyriazopoulou VE, et al. Differential expression of microRNAs in adipose tissue after long-term high-fat diet-induced obesity in mice. PLoS One. 2012;7(4):e34872.PubMedPubMedCentral
85.
Bhaumik D, Scott GK, Schokrpur S, Patil CK, Orjalo AV, Rodier F, et al. MicroRNAs miR-146a/b negatively modulate the senescence-associated inflammatory mediators IL-6 and IL-8. Aging. 2009;1(4):402.PubMedPubMedCentral
86.
Boldin MP, Taganov KD, Rao DS, Yang L, Zhao JL, Kalwani M, et al. miR-146a is a significant brake on autoimmunity, myeloproliferation, and cancer in mice. J Exp Med. 2011;208(6):1189–201.PubMedPubMedCentral
87.
Wu D, Xi Q-Y, Cheng X, Dong T, Zhu X-T, Shu G et al. miR-146a-5p inhibits TNF-α-induced adipogenesis via targeting insulin receptor in primary porcine adipocytes. Journal of lipid research. 2016:jlr. M062497.
88.
Roos J, Enlund E, Funcke J-B, Tews D, Holzmann K, Debatin K-M, et al. miR-146a-mediated suppression of the inflammatory response in human adipocytes. Sci Rep. 2016;6:38339.PubMedPubMedCentral
89.
Jiang X, Xue M, Fu Z, Ji C, Guo X, Zhu L, et al. Insight into the effects of adipose tissue inflammation factors on miR-378 expression and the underlying mechanism. Cell Physiol Biochem. 2014;33(6):1778–88.PubMed
90.
Xu L-l, Shi C-m, Xu G-f, Chen L, Zhu L-l, Zhu L, et al. TNF-α, IL-6, and leptin increase the expression of miR-378, an adipogenesis-related microRNA in human adipocytes. Cell Biochem Biophys. 2014;70(2):771–6.PubMed
91.
Ishida M, Shimabukuro M, Yagi S, Nishimoto S, Kozuka C, Fukuda D, et al. MicroRNA-378 regulates adiponectin expression in adipose tissue: a new plausible mechanism. PLoS One. 2014;9(11):e111537.PubMedPubMedCentral
92.
Li R, Shen Q, Wu N, He M, Liu N, Huang J, et al. MiR-145 improves macrophage-mediated inflammation through targeting Arf6. Endocrine. 2018;60(1):73–82.PubMed
93.
Arner P, Kulyté A. MicroRNA regulatory networks in human adipose tissue and obesity. Nat Rev Endocrinol. 2015;11(5):276.PubMed
94.
Fehlmann T, Ludwig N, Backes C, Meese E, Keller A. Distribution of microRNA biomarker candidates in solid tissues and body fluids. RNA Biol. 2016;13(11):1084–8.PubMedPubMedCentral
95.
Martinelli R, Nardelli C, Pilone V, Buonomo T, Liguori R, Castanò I, et al. miR-519d overexpression is associated with human obesity. Obesity. 2010;18(11):2170–6.PubMed
96.
Ortega FJ, Moreno-Navarrete JM, Pardo G, Sabater M, Hummel M, Ferrer A, et al. MiRNA expression profile of human subcutaneous adipose and during adipocyte differentiation. PLoS One. 2010;5(2):e9022.PubMedPubMedCentral
97.
Arner E, Mejhert N, Kulyté A, Balwierz PJ, Pachkov M, Cormont M, et al. Adipose tissue microRNAs as regulators of CCL2 production in human obesity. Diabetes. 2012;61(8):1986–93.PubMedPubMedCentral
98.
Arner E, Mejhert N, Kulyté A, Balwierz PJ, Pachkov M, Cormont M et al. Adipose tissue microRNAs as regulators of CCL2 production in human obesity. Diabetes. 2012:DB_111508.
99.
Lorente-Cebrián S, Mejhert N, Kulyté A, Laurencikiene J, Åström G, Hedén P, et al. MicroRNAs regulate human adipocyte lipolysis: effects of miR-145 are linked to TNF-α. PLoS One. 2014;9(1):e86800.PubMedPubMedCentral
100.
Zhu L, Chen L, Shi C-M, Xu G-F, Xu L-L, Zhu L-L, et al. MiR-335, an adipogenesis-related microRNA, is involved in adipose tissue inflammation. Cell Biochem Biophys. 2014;68(2):283–90.PubMed
101.
Chen Y, Siegel F, Kipschull S, Haas B, Fröhlich H, Meister G, et al. miR-155 regulates differentiation of brown and beige adipocytes via a bistable circuit. Nat Commun. 2013;4:1769.PubMedPubMedCentral
102.
Parra P, Serra F, Palou A. Expression of adipose microRNAs is sensitive to dietary conjugated linoleic acid treatment in mice. PLoS One. 2010;5(9):e13005.PubMedPubMedCentral
103.
Meerson A, Traurig M, Ossowski V, Fleming J, Mullins M, Baier L. Human adipose microRNA-221 is upregulated in obesity and affects fat metabolism downstream of leptin and TNF-α. Diabetologia. 2013;56(9):1971–9.PubMedPubMedCentral
104.
105.
106.
107.
Bala S, Marcos M, Kodys K, Csak T, Catalano D, Mandrekar P, et al. Up-regulation of microRNA-155 in macrophages contributes to increased tumor necrosis factor α (TNFα) production via increased mRNA half-life in alcoholic liver disease. J Biol Chem. 2011;286(2):1436–44.PubMed
108.
Tili E, Michaille J-J, Cimino A, Costinean S, Dumitru CD, Adair B, et al. Modulation of miR-155 and miR-125b levels following lipopolysaccharide/TNF-α stimulation and their possible roles in regulating the response to endotoxin shock. J Immunol. 2007;179(8):5082–9.PubMed
109.
O'connell RM, Kahn D, Gibson WS, Round JL, Scholz RL, Chaudhuri AA, et al. MicroRNA-155 promotes autoimmune inflammation by enhancing inflammatory T cell development. Immunity. 2010;33(4):607–19.PubMedPubMedCentral
110.
Li Y, Zhao L, Shi B, Ma S, Xu Z, Ge Y, et al. Functions of miR-146a and miR-222 in tumor-associated macrophages in breast cancer. Sci Rep. 2015;5:18648.PubMedPubMedCentral
111.
Bao M-h, Li J-M, Luo H-q, Tang L, Lv, Q-l, Li G-y et al. NF-κB-regulated miR-99a modulates endothelial cell inflammation. Mediators of inflammation. 2016;2016.
112.
Banerjee S, Cui H, Xie N, Tan Z, Yang S, Icyuz M, et al. miR-125a-5p regulates differential activation of macrophages and inflammation. J Biol Chem. 2013;288(49):35428–36.PubMedPubMedCentral
113.
Deiuliis JA, Syed R, Duggineni D, Rutsky J, Rengasamy P, Zhang J, et al. Visceral adipose microRNA 223 is upregulated in human and murine obesity and modulates the inflammatory phenotype of macrophages. PLoS One. 2016;11(11):e0165962.PubMedPubMedCentral
114.
Ibrahim MM. Subcutaneous and visceral adipose tissue: structural and functional differences. Obes Rev. 2010;11(1):11–8.PubMed
115.
Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. The Journal of Clinical Endocrinology & Metabolism. 2004;89(6):2548–56.
116.
Haneklaus M, Gerlic M, Kurowska-Stolarska M, Rainey A-A, Pich D, McInnes IB, et al. Cutting edge: miR-223 and EBV miR-BART15 regulate the NLRP3 inflammasome and IL-1β production. J Immunol. 2012;189(8):3795–9.PubMed
117.
Chen L, Dai Y-M, Ji C-B, Yang L, Shi C-M, Xu G-F, et al. MiR-146b is a regulator of human visceral preadipocyte proliferation and differentiation and its expression is altered in human obesity. Mol Cell Endocrinol. 2014;393(1–2):65–74.PubMed
118.
Munetsuna E, Yamada H, Ando Y, Yamazaki M, Tsuboi Y, Kondo M et al. Association of subcutaneous and visceral fat with circulating microRNAs in a middle-aged Japanese population. Ann Clin Biochem 2017:0004563217735124.
119.
Xie W, Li Z, Li M, Xu N, Zhang Y. miR-181a and inflammation: miRNA homeostasis response to inflammatory stimuli in vivo. Biochem Biophys Res Commun. 2013;430(2):647–52.PubMed
120.
Yu J, Kong X, Liu J, Lv Y, Sheng Y, Lv S, et al. Expression profiling of PPARγ-regulated microRNAs in human subcutaneous and visceral adipogenesis in both genders. Endocrinology. 2014;155(6):2155–65.PubMed
121.
Estep M, Armistead D, Hossain N, Elarainy H, Goodman Z, Baranova A, et al. Differential expression of miRNAs in the visceral adipose tissue of patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2010;32(3):487–97.PubMed
122.
Gerin I, Clerbaux L-A, Haumont O, Lanthier N, Das AK, Burant CF, et al. Expression of miR-33 from an SREBP2 intron inhibits cholesterol export and fatty acid oxidation. J Biol Chem. 2010;285(44):33652–61.PubMedPubMedCentral
123.
Goedeke L, Vales-Lara FM, Fenstermaker M, Cirera-Salinas D, Chamorro-Jorganes A, Ramírez CM, et al. A regulatory role for microRNA 33* in controlling lipid metabolism gene expression. Mol Cell Biol. 2013;33(11):2339–52.PubMedPubMedCentral
124.
Ferrante SC, Nadler EP, Pillai DK, Hubal MJ, Wang Z, Wang JM, et al. Adipocyte-derived exosomal miRNAs: a novel mechanism for obesity-related disease. Pediatr Res. 2015;77(3):447.PubMed
125.
126.
Nakanishi N, Nakagawa Y, Tokushige N, Aoki N, Matsuzaka T, Ishii K, et al. The up-regulation of microRNA-335 is associated with lipid metabolism in liver and white adipose tissue of genetically obese mice. Biochem Biophys Res Commun. 2009;385(4):492–6.PubMed
127.
Xu J, Hu G, Lu M, Xiong Y, Li Q, Chang CC, et al. MiR-9 reduces human acyl-coenzyme a: cholesterol acyltransferase-1 to decrease THP-1 macrophage-derived foam cell formation. Acta Biochim Biophys Sin. 2013;45(11):953–62.PubMed
128.
Wen J, Friedman JR. miR-122 regulates hepatic lipid metabolism and tumor suppression. J Clin Invest. 2012;122(8):2773–6.PubMedPubMedCentral
129.
Esau C, Davis S, Murray SF, Yu XX, Pandey SK, Pear M, et al. miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab. 2006;3(2):87–98.PubMed
130.
Karbiener M, Fischer C, Nowitsch S, Opriessnig P, Papak C, Ailhaud G, et al. microRNA miR-27b impairs human adipocyte differentiation and targets PPARγ. Biochem Biophys Res Commun. 2009;390(2):247–51.PubMed
131.
Vickers KC, Shoucri BM, Levin MG, Wu H, Pearson DS, Osei-Hwedieh D, et al. MicroRNA-27b is a regulatory hub in lipid metabolism and is altered in dyslipidemia. Hepatology. 2013;57(2):533–42.PubMed
132.
de Aguiar Vallim TQ, Tarling EJ, Kim T, Civelek M, Baldán Á, Esau C, et al. MicroRNA-144 regulates hepatic ATP binding cassette transporter A1 and plasma high-density lipoprotein after activation of the nuclear receptor Farnesoid X ReceptorNovelty and significance. Circ Res. 2013;112(12):1602–12.PubMedPubMedCentral
133.
Ramírez CM, Rotllan N, Vlassov AV, Dávalos A, Li M, Goedeke L, et al. Control of cholesterol metabolism and plasma high-density lipoprotein levels by microRNA-144. Circ Res. 2013;112(12):1592–601.PubMedPubMedCentral
134.
Goedeke L, Vales-Lara FM, Fenstermaker M, Cirera-Salinas D, Chamorro-Jorganes A, Ramírez CM et al. A regulatory role for miRNA-33* in controlling lipid metabolism gene expression. Molecular and cellular biology. 2013:MCB. 01714–12.
135.
Gerin I, Clerbaux L-A, Haumont O, Lanthier N, Das AK, Burant CF et al. Expression of miR-33 from an SREBP2 intron inhibits cholesterol export and fatty acid oxidation. Journal of Biological Chemistry. 2010:jbc. M110. 152090.
136.
Fernández-Hernando C, Suárez Y, Rayner KJ, Moore KJ. MicroRNAs in lipid metabolism. Curr Opin Lipidol. 2011;22(2):86.PubMedPubMedCentral
137.
Gerin I, Bommer GT, McCoin CS, Sousa KM, Krishnan V, MacDougald OA. Roles for miRNA-378/378* in adipocyte gene expression and lipogenesis. American Journal of Physiology-Endocrinology and Metabolism. 2010;299(2):E198–206.PubMedPubMedCentral
138.
Carrer M, Liu N, Grueter CE, Williams AH, Frisard MI, Hulver MW, et al. Control of mitochondrial metabolism and systemic energy homeostasis by microRNAs 378 and 378. Proc Natl Acad Sci. 2012;201207605.
139.
Chen T, Yan H, Li Z, Jing T, Zhu W, Ge J, et al. MicroRNA-155 regulates lipid uptake, adhesion/chemokine marker secretion and SCG2 expression in oxLDL-stimulated dendritic cells/macrophages. Int J Cardiol. 2011;147(3):446–7.PubMed
140.
Novák J, Bienertová-Vašků J, Kára T, Novák M. MicroRNAs involved in the lipid metabolism and their possible implications for atherosclerosis development and treatment. Mediators of inflammation. 2014;2014.
141.
Chen T, Huang Z, Wang L, Wang Y, Wu F, Meng S, et al. MicroRNA-125a-5p partly regulates the inflammatory response, lipid uptake, and ORP9 expression in oxLDL-stimulated monocyte/macrophages. Cardiovasc Res. 2009;83(1):131–9.PubMed
142.
Vickers KC, Landstreet SR, Levin MG, Shoucri BM, Toth CL, Taylor RC, et al. MicroRNA-223 coordinates cholesterol homeostasis. Proc Natl Acad Sci. 2014;111(40):14518–23.PubMed
143.
Jones S, Watkins G, Le Good N, Roberts S, Murphy C, Brockbank S, et al. The identification of differentially expressed microRNA in osteoarthritic tissue that modulate the production of TNF-α and MMP13. Osteoarthr Cartil. 2009;17(4):464–72.PubMed
144.
145.
S-h H, Wang B, Kota J, Yu J, Costinean S, Kutay H, et al. Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver. J Clin Invest. 2012;122(8):2871–83.
146.
Chen Y, Wang C, Liu Y, Tang L, Zheng M, Xu C, et al. miR-122 targets NOD2 to decrease intestinal epithelial cell injury in Crohn’s disease. Biochem Biophys Res Commun. 2013;438(1):133–9.PubMed
147.
Lee J-J, Drakaki A, Iliopoulos D, Struhl K. MiR-27b targets PPARγ to inhibit growth, tumor progression and the inflammatory response in neuroblastoma cells. Oncogene. 2012;31(33):3818.PubMed
148.
Liu H. Down-regulation of miR-144 after mycobacterium tuberculosis infection promotes inflammatory factor secretion from macrophages through the Tpl2/ERK pathway. Cell Mol Biol. 2016;62(2):87–93.PubMed
149.
Baba O, Horie T, Nakao T, Hakuno D, Nakashima Y, Nishi H et al. MicroRNA-33 regulates the population of peripheral inflammatory Ly6Chigh monocytes through dual pathways. Molecular and cellular biology. 2018:MCB. 00604–17.
150.
Xie Q, Wei M, Zhang B, Kang X, Liu D, Zheng W, et al. MicroRNA-33 regulates the NLRP3 inflammasome signaling pathway in macrophages. Mol Med Rep. 2018;17(2):3318–27.PubMed
151.
Liu S, Yang Y, Wu J. TNFα-induced up-regulation of miR-155 inhibits adipogenesis by down-regulating early adipogenic transcription factors. Biochem Biophys Res Commun. 2011;414(3):618–24.PubMed
152.
Skårn M, Namløs HM, Noordhuis P, Wang M-Y, Meza-Zepeda LA, Myklebost O. Adipocyte differentiation of human bone marrow-derived stromal cells is modulated by microRNA-155, microRNA-221, and microRNA-222. Stem Cells Dev. 2011;21(6):873–83.PubMed
153.
154.
Hulsmans M, De Keyzer D, Holvoet P. MicroRNAs regulating oxidative stress and inflammation in relation to obesity and atherosclerosis. FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 2011;25(8):2515–27. https://​doi.​org/​10.​1096/​fj.​11-181149.CrossRef
155.
Wang Q, Li YC, Wang J, Kong J, Qi Y, Quigg RJ, et al. miR-17-92 cluster accelerates adipocyte differentiation by negatively regulating tumor-suppressor Rb2/p130. Proc Natl Acad Sci. 2008;105(8):2889–94.PubMed
156.
157.
Ando Y, Yang G-X, Kenny TP, Kawata K, Zhang W, Huang W, et al. Overexpression of microRNA-21 is associated with elevated pro-inflammatory cytokines in dominant-negative TGF-β receptor type II mouse. J Autoimmun. 2013;41:111–9.PubMedPubMedCentral
158.
159.
Sun T, Fu M, Bookout AL, Kliewer SA, Mangelsdorf DJ. MicroRNA let-7 regulates 3T3-L1 adipogenesis. Mol Endocrinol. 2009;23(6):925–31.PubMedPubMedCentral
160.
Lin Q, Gao Z, Alarcon RM, Ye J, Yun Z. A role of miR-27 in the regulation of adipogenesis. FEBS J. 2009;276(8):2348–58.PubMedPubMedCentral
161.
Polikepahad S, Knight JM, Naghavi AO, Oplt T, Creighton CJ, Shaw C et al. Pro-inflammatory role for let-7 microRNAs in experimental asthma. Journal of Biological Chemistry. 2010:jbc. M110. 145698.
162.
Kumar M, Ahmad T, Sharma A, Mabalirajan U, Kulshreshtha A, Agrawal A, et al. Let-7 microRNA–mediated regulation of IL-13 and allergic airway inflammation. J Allergy Clin Immunol. 2011;128(5):1077–85 e10.PubMed
163.
Lin Z, Ge J, Wang Z, Ren J, Wang X, Xiong H, et al. Let-7e modulates the inflammatory response in vascular endothelial cells through ceRNA crosstalk. Sci Rep. 2017;7:42498.PubMedPubMedCentral
164.
Iliopoulos D, Hirsch HA, Struhl K. An epigenetic switch involving NF-κB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation. Cell. 2009;139(4):693–706.PubMedPubMedCentral
165.
Kumar M, Sahu SK, Kumar R, Subuddhi A, Maji RK, Jana K, et al. MicroRNA let-7 modulates the immune response to mycobacterium tuberculosis infection via control of A20, an inhibitor of the NF-κB pathway. Cell Host Microbe. 2015;17(3):345–56.PubMed
166.
Hosogai N, Fukuhara A, Oshima K, Miyata Y, Tanaka S, Segawa K, et al. Adipose tissue hypoxia in obesity and its impact on adipocytokine dysregulation. Diabetes. 2007;56(4):901–11.PubMed
167.
Taganov KD, Boldin MP, Chang K-J, Baltimore D. NF-κB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci. 2006;103(33):12481–6.PubMed
168.
169.
170.
Ling HY, Wen GB, Feng SD, Tuo QH, Ou HS, Yao CH, et al. MicroRNA-375 promotes 3T3-L1 adipocyte differentiation through modulation of extracellular signal-regulated kinase signalling. Clin Exp Pharmacol Physiol. 2011;38(4):239–46.PubMedPubMedCentral
171.
Garikipati VN, Verma SK, Jolardarashi D, Cheng Z, Ibetti J, Cimini M, et al. Therapeutic inhibition of miR-375 attenuates post-myocardial infarction inflammatory response and left ventricular dysfunction via PDK-1-AKT signalling axis. Cardiovasc Res. 2017;113(8):938–49.PubMed
172.
Lei L, Zhou C, Yang X, Li L. Down-regulation of micro RNA-375 regulates adipokines and inhibits inflammatory cytokines by targeting AdipoR2 in non-alcoholic fatty liver disease. Clinical and Experimental Pharmacology and Physiology. 2018.
173.
Li Y, Zu L, Wang Y, Wang M, Chen P, Zhou Q. miR-132 inhibits lung cancer cell migration and invasion by targeting SOX4. Journal of Thoracic Disease. 2015;7(9):1563.PubMedPubMedCentral
174.
He L, Qu L, Wei L, Chen Y, Suo J. Reduction of miR-132-3p contributes to gastric cancer proliferation by targeting MUC13. Mol Med Rep. 2017;15(5):3055–61.PubMedPubMedCentral
175.
Zheng Y-B, Luo H-P, Shi Q, Hao Z-N, Ding Y, Wang Q-S, et al. miR-132 inhibits colorectal cancer invasion and metastasis via directly targeting ZEB2. World J Gastroenterol: WJG. 2014;20(21):6515.PubMed
176.
Zhang Z-G, Chen W-X, Wu Y-H, Liang H-F, Zhang B-X. MiR-132 prohibits proliferation, invasion, migration, and metastasis in breast cancer by targeting HN1. Biochem Biophys Res Commun. 2014;454(1):109–14.PubMed
177.
Park J-K, Henry JC, Jiang J, Esau C, Gusev Y, Lerner MR, et al. miR-132 and miR-212 are increased in pancreatic cancer and target the retinoblastoma tumor suppressor. Biochem Biophys Res Commun. 2011;406(4):518–23.PubMedPubMedCentral
178.
Laios A, O'Toole S, Flavin R, Martin C, Kelly L, Ring M, et al. Potential role of miR-9 and miR-223 in recurrent ovarian cancer. Mol Cancer. 2008;7(1):35.PubMedPubMedCentral
179.
Lehmann U, Hasemeier B, Christgen M, Müller M, Römermann D, Länger F, et al. Epigenetic inactivation of microRNA gene hsa-mir-9-1 in human breast cancer. The Journal of Pathology: A Journal of the Pathological Society of Great Britain and Ireland. 2008;214(1):17–24.
180.
Tsai K-W, Liao Y-L, Wu C-W, Hu L-Y, Li S-C, Chan W-C, et al. Aberrant hypermethylation of miR-9 genes in gastric cancer. Epigenetics. 2011;6(10):1189–97.PubMedPubMedCentral
181.
Selcuklu SD, Donoghue MT, Rehmet K, de Souza Gomes M, Fort A, Kovvuru P et al. MicroRNA-9 inhibition of cell proliferation and identification of novel miR-9 targets by transcriptome profiling in breast cancer cells. Journal of Biological Chemistry. 2012:jbc. M111. 335943.
182.
Cekaite L, Rantala JK, Bruun J, Guriby M, Ågesen TH, Danielsen SA, et al. MiR-9,-31, and-182 deregulation promote proliferation and tumor cell survival in colon cancer. Neoplasia. 2012;14(9):IN20–IN1.
183.
Ma L, Young J, Prabhala H, Pan E, Mestdagh P, Muth D, et al. miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat Cell Biol. 2010;12(3):247.PubMedPubMedCentral
184.
Park S-Y, Lee JH, Ha M, Nam J-W, Kim VN. miR-29 miRNAs activate p53 by targeting p85α and CDC42. Nat Struct Mol Biol. 2009;16(1):23.PubMed
185.
Jiang H, Zhang G, Wu J-H, Jiang C-P. Diverse roles of miR-29 in cancer. Oncol Rep. 2014;31(4):1509–16.PubMed
186.
Spizzo R, Nicoloso M, Lupini L, Lu Y, Fogarty J, Rossi S, et al. miR-145 participates with TP53 in a death-promoting regulatory loop and targets estrogen receptor-α in human breast cancer cells. Cell Death Differ. 2010;17(2):246.PubMed
187.
Sachdeva M, Zhu S, Wu F, Wu H, Walia V, Kumar S, et al. p53 represses c-Myc through induction of the tumor suppressor miR-145. Proc Natl Acad Sci. 2009;106(9):3207–12.PubMed
188.
Wang S, Bian C, Yang Z, Bo Y, Li J, Zeng L, et al. miR-145 inhibits breast cancer cell growth through RTKN. Int J Oncol. 2009;34(5):1461–6.PubMed
189.
Chiyomaru T, Enokida H, Tatarano S, Kawahara K, Uchida Y, Nishiyama K, et al. miR-145 and miR-133a function as tumour suppressors and directly regulate FSCN1 expression in bladder cancer. Br J Cancer. 2010;102(5):883.PubMedPubMedCentral
190.
Slaby O, Svoboda M, Fabian P, Smerdova T, Knoflickova D, Bednarikova M, et al. Altered expression of miR-21, miR-31, miR-143 and miR-145 is related to clinicopathologic features of colorectal cancer. Oncology. 2007;72(5–6):397–402.PubMed
191.
Xu Q, Liu L-Z, Qian X, Chen Q, Jiang Y, Li D, et al. MiR-145 directly targets p70S6K1 in cancer cells to inhibit tumor growth and angiogenesis. Nucleic Acids Res. 2011;40(2):761–74.PubMedPubMedCentral
192.
Arndt GM, Dossey L, Cullen LM, Lai A, Druker R, Eisbacher M, et al. Characterization of global microRNA expression reveals oncogenic potential of miR-145 in metastatic colorectal cancer. BMC Cancer. 2009;9(1):374.PubMedPubMedCentral
193.
Huang S, Chen Y, Wu W, Ouyang N, Chen J, Li H, et al. miR-150 promotes human breast cancer growth and malignant behavior by targeting the pro-apoptotic purinergic P2X7 receptor. PLoS One. 2013;8(12):e80707.PubMedPubMedCentral
194.
Zhang N, Wei X, Xu L. miR-150 promotes the proliferation of lung cancer cells by targeting P53. FEBS Lett. 2013;587(15):2346–51.PubMed
195.
Wu Q, Jin H, Yang Z, Luo G, Lu Y, Li K, et al. MiR-150 promotes gastric cancer proliferation by negatively regulating the pro-apoptotic gene EGR2. Biochem Biophys Res Commun. 2010;392(3):340–5.PubMed
196.
Farhana L, Dawson MI, Murshed F, Das JK, Rishi AK, Fontana JA. Upregulation of miR-150* and miR-630 induces apoptosis in pancreatic cancer cells by targeting IGF-1R. PLoS One. 2013;8(5):e61015.PubMedPubMedCentral
197.
Ma Y, Zhang P, Wang F, Zhang H, Yang J, Peng J, et al. miR-150 as a potential biomarker associated with prognosis and therapeutic outcome in colorectal cancer. Gut. 2012;61(10):1447–53.PubMed
198.
Hu Y, Zhu Q, Tang L. MiR-99a antitumor activity in human breast cancer cells through targeting of mTOR expression. PLoS One. 2014;9(3):e92099.PubMedPubMedCentral
199.
Huang H-G, Luo X, Wu S, Jian B. MiR-99a inhibits cell proliferation and tumorigenesis through targeting mTOR in human anaplastic thyroid cancer. Asian Pac J Cancer Prev. 2015;16(12):4937–44.PubMed
200.
Yin H, Ma J, Chen L, Piao S, Zhang Y, Zhang S, et al. MiR-99a enhances the radiation sensitivity of non-small cell lung Cancer by targeting mTOR. Cell Physiol Biochem. 2018;46(2):471–81.PubMed
201.
Teng Y, Zhang R, Liu C, Zhou L, Wang H, Zhuang W, et al. miR-143 inhibits interleukin-13-induced inflammatory cytokine and mucus production in nasal epithelial cells from allergic rhinitis patients by targeting IL13Rα1. Biochem Biophys Res Commun. 2015;457(1):58–64.PubMed
202.
Zhang Q, Feng Y, Liu P, Yang J. MiR-143 inhibits cell proliferation and invasion by targeting DNMT3A in gastric cancer. Tumor Biol. 2017;39(7):1010428317711312.
203.
He Z, Yi J, Liu X, Chen J, Han S, Jin L, et al. MiR-143-3p functions as a tumor suppressor by regulating cell proliferation, invasion and epithelial–mesenchymal transition by targeting QKI-5 in esophageal squamous cell carcinoma. Mol Cancer. 2016;15(1):51.PubMedPubMedCentral
204.
Peng J, Zhou Y, Deng Z, Zhang H, Wu Y, Song T et al. miR-221 negatively regulates inflammation and insulin sensitivity in white adipose tissue by repression of sirtuin-1 (SIRT1). Journal of cellular biochemistry. 2017.
205.
Garofalo M, Quintavalle C, Romano G, Croce MC, Condorelli G. miR221/222 in cancer: their role in tumor progression and response to therapy. Curr Mol Med. 2012;12(1):27–33.PubMedPubMedCentral
206.
Yang C, Tabatabaei SN, Ruan X, Hardy P. The dual regulatory role of MiR-181a in breast Cancer. Cell Physiol Biochem. 2017;44(3):843–56.PubMed
207.
Parikh A, Lee C, Joseph P, Marchini S, Baccarini A, Kolev V, et al. microRNA-181a has a critical role in ovarian cancer progression through the regulation of the epithelial–mesenchymal transition. Nat Commun. 2014;5:2977.PubMedPubMedCentral
208.
Lin Y, Zhao J, Wang H, Cao J, Nie Y. miR-181a modulates proliferation, migration and autophagy in AGS gastric cancer cells and downregulates MTMR3. Mol Med Rep. 2017;15(5):2451–6.PubMedPubMedCentral
209.
Shin K-H, Bae SD, Hong HS, Kim RH, Kang MK, Park N-H. miR-181a shows tumor suppressive effect against oral squamous cell carcinoma cells by downregulating K-ras. Biochem Biophys Res Commun. 2011;404(4):896–902.PubMed
210.
Sun X, Sit A, Feinberg MW. Role of miR-181 family in regulating vascular inflammation and immunity. Trends in Cardiovascular Medicine. 2014;24(3):105–12.PubMed
211.
Liu J, Shi W, Wu C, Ju J, Jiang J. miR-181b as a key regulator of the oncogenic process and its clinical implications in cancer. Biomedical Reports. 2014;2(1):7–11.PubMed
212.
Sun X, Liu J, Xu C, Tang SC, Ren H. The insights of Let-7 miRNAs in oncogenesis and stem cell potency. J Cell Mol Med. 2016;20(9):1779–88.PubMedPubMedCentral
213.
Boyerinas B, Park S-M, Hau A, Murmann AE, Peter ME. The role of let-7 in cell differentiation and cancer. Endocr Relat Cancer. 2010;17(1):F19–36.PubMed
214.
Yan Z, Xiong Y, Xu W, Gao J, Cheng Y, Wang Z, et al. Identification of hsa-miR-335 as a prognostic signature in gastric cancer. PLoS One. 2012;7(7):e40037.PubMedPubMedCentral
215.
Gao Y, Zeng F, Wu J-Y, Li H-Y, Fan J-J, Mai L, et al. MiR-335 inhibits migration of breast cancer cells through targeting oncoprotein c-met. Tumor Biol. 2015;36(4):2875–83.
216.
Liu J, Bian T, Feng J, Qian L, Zhang J, Jiang D, et al. miR-335 inhibited cell proliferation of lung cancer cells by target Tra2β. Cancer Sci. 2018;109(2):289–96.PubMed
217.
Chen C-YA, Chang JT, Ho Y-F, Shyu A-B. MiR-26 down-regulates TNF-α/NF-κB signalling and IL-6 expression by silencing HMGA1 and MALT1. Nucleic Acids Res. 2016;44(8):3772–87.PubMedPubMedCentral
218.
Liu X-X, Li X-J, Zhang B, Liang Y-J, Zhou C-X, Cao D-X, et al. MicroRNA-26b is underexpressed in human breast cancer and induces cell apoptosis by targeting SLC7A11. FEBS Lett. 2011;585(9):1363–7.PubMed
219.
Verghese ET, Drury R, Green CA, Holliday DL, Lu X, Nash C, et al. MiR-26b is down-regulated in carcinoma-associated fibroblasts from ER-positive breast cancers leading to enhanced cell migration and invasion. J Pathol. 2013;231(3):388–99.PubMedPubMedCentral
220.
Zhuang G, Meng C, Guo X, Cheruku PS, Shi L, Xu H et al. A novel regulator of macrophage activation: miR-223 in obesity associated adipose tissue inflammation. Circulation. 2012:CIRCULATIONAHA. 111.087817.
221.
Taïbi F, Metzinger-Le Meuth V, Massy ZA, Metzinger L. miR-223: an inflammatory oncomiR enters the cardiovascular field. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease. 2014;1842(7):1001–9.
222.
Li X-Q, Yu Q, Tan W-F, Zhang Z-L, Ma H. MicroRNA-125b mimic inhibits ischemia reperfusion-induced neuroinflammation and aberrant p53 apoptotic signalling activation through targeting TP53INP1. Brain Behav Immun. 2018;74:154–65.PubMed
223.
Le MT, Shyh-Chang N, Khaw SL, Chin L, Teh C, Tay J, et al. Conserved regulation of p53 network dosage by microRNA–125b occurs through evolving miRNA–target gene pairs. PLoS Genet. 2011;7(9):e1002242.PubMedPubMedCentral
224.
Diao W, Lu L, Li S, Chen J, Zen K, Li L. MicroRNA-125b-5p modulates the inflammatory state of macrophages via targeting B7-H4. Biochem Biophys Res Commun. 2017;491(4):912–8.PubMed
225.
Zhang B, Wang L-S, Zhou Y-H. Elevated microRNA-125b promotes inflammation in rheumatoid arthritis by activation of NF-κB pathway. Biomed Pharmacother. 2017;93:1151–7.PubMed
226.
Zhang L, Ge Y, Fuchs E. miR-125b can enhance skin tumor initiation and promote malignant progression by repressing differentiation and prolonging cell survival. Genes Dev. 2014;28(22):2532–46.PubMedPubMedCentral
227.
Huang K, Dong S, Li W, Xie Z. The expression and regulation of microRNA-125b in cancers. Acta Biochim Biophys Sin. 2013;45(10):803–5.PubMed
228.
Budd WT, Seashols-Williams SJ, Clark GC, Weaver D, Calvert V, Petricoin E, et al. Dual action of miR-125b as a tumor suppressor and oncomiR-22 promotes prostate cancer tumorigenesis. PLoS One. 2015;10(11):e0142373.PubMedPubMedCentral
229.
Yang CH, Pfeffer SR, Sims M, Yue J, Wang Y, Linga VG, et al. The oncogenic microRNA-21 inhibits the tumor suppressive activity of FBXO11 to promote tumorigenesis. J Biol Chem. 2015;290(10):6037–46.PubMedPubMedCentral
230.
Yan L-X, Huang X-F, Shao Q, Huang M-Y, Deng L, Wu Q-L, et al. MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. Rna. 2008;14(11):2348–60.PubMedPubMedCentral
231.
Li X, Kong D, Chen H, Liu S, Hu H, Wu T, et al. miR-155 acts as an anti-inflammatory factor in atherosclerosis-associated foam cell formation by repressing calcium-regulated heat stable protein 1. Sci Rep. 2016;6:21789.PubMedPubMedCentral
232.
Ye J, Guo R, Shi Y, Qi F, Guo C, Yang L. miR-155 regulated inflammation response by the SOCS1-STAT3-PDCD4 axis in atherogenesis. Mediators of inflammation. 2016;2016.
233.
Liu J, Chen Z, Xiang J, Gu X. MicroRNA-155 acts as a tumor suppressor in colorectal cancer by targeting CTHRC1 in vitro. Oncol Lett. 2018;15(4):5561–8.PubMedPubMedCentral
234.
Mattiske S, Suetani RJ, Neilsen PM, Callen DF. The oncogenic role of miR-155 in breast cancer. Cancer Epidemiology and Prevention Biomarkers. 2012;21(8):1236–43.
235.
Bleau A-M, Redrado M, Nistal-Villan E, Villalba M, Exposito F, Redin E, et al. miR-146a targets c-met and abolishes colorectal cancer liver metastasis. Cancer Lett. 2018;414:257–67.PubMed
236.
Li Y, Xu Y, Yu C, Zuo W. Associations of miR-146a and miR-146b expression and breast cancer in very young women. Cancer Biomarkers. 2015;15(6):881–7.PubMed
237.
Pfeiffer D, Roßmanith E, Lang I, Falkenhagen D. miR-146a, miR-146b, and miR-155 increase expression of IL-6 and IL-8 and support HSP10 in an in vitro sepsis model. PLoS One. 2017;12(6):e0179850.PubMedPubMedCentral
Metadata
Title
Inflammation related miRNAs as an important player between obesity and cancers
Authors
Morteza Gholami
Bagher Larijani
Zhila Zahedi
Fatemeh Mahmoudian
Samira Bahrami
Sima Parvizi Omran
Zahra Saadatian
Shirin Hasani-Ranjbar
Reza Taslimi
Milad Bastami
Mahsa M. Amoli
Publication date
01-12-2019
Publisher
Springer International Publishing
Published in
Journal of Diabetes & Metabolic Disorders / Issue 2/2019
Electronic ISSN: 2251-6581
DOI
https://doi.org/10.1007/s40200-019-00459-2

Other articles of this Issue 2/2019

Journal of Diabetes & Metabolic Disorders 2/2019 Go to the issue

Commentary

Conceptual map of diabetes education: necessity of establishing iran diabetes academy

Research article

Efficacy of melatonin in restoring the antioxidant status in the lens of diabetic rats induced by streptozotocin

Research article

Determining minimum set of features for diabetes mobile apps

Research article

Identification and performance of multiple clinical and laboratorial risk factors for diagnosis of cardiac autonomic neuropathy in type 1 diabetes patients

Research article

Lean body mass and risk of type 2 diabetes - a Danish cohort study

Research article

DM-calendar app as a diabetes self-management education on adult type 2 diabetes mellitus: a randomized controlled trial

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits